# OnCo record regorafenib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/regorafenib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "regorafenib" ;
  schema:name "Regorafenib"@en ;
  schema:description "A sorafenib successor that became the first second-line drug proven to prolong life in liver cancer (2017)."@en ;
  schema:url <https://onco.cc/drugs/regorafenib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Regorafenib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q3891664> ;
  schema:citation <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/203085s013lbl.pdf>, <https://www.nice.org.uk/guidance/ta866>, <https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga> ;
  onco:status "approved" ;
  onco:modality "Small-molecule multi-kinase inhibitor" ;
  schema:alternateName "Stivarga" ;
  onco:approval "US 2012: Metastatic colorectal cancer, previously treated", "US 2013: GIST after imatinib and sunitinib", "US 2017: HCC previously treated with sorafenib", "US 2012: Metastatic colorectal cancer after fluoropyrimidine, oxaliplatin, irinotecan, anti-VEGF and, if RAS wild-type, anti-EGFR therapy", "EU 2013: Metastatic colorectal cancer after available therapies", "England (NICE) 2023: Metastatic colorectal cancer after previous treatment or when those treatments are unsuitable" ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-advanced/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/sarcoma/>, <https://onco.cc/cancers/gist-imatinib-resistant/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/antiangiogenic/> ;
  onco:targets <https://onco.cc/targets/vegf/>, <https://onco.cc/targets/kit/>, <https://onco.cc/targets/ret/> ;
  onco:companies <https://onco.cc/companies/bayer/> ;
  onco:trials <https://onco.cc/trials/resorce/>, <https://onco.cc/trials/nct06199973/>, <https://onco.cc/trials/nct05425940/>, <https://onco.cc/trials/nct04701476/>, <https://onco.cc/trials/nct02955940/>, <https://onco.cc/trials/nct07310173/>, <https://onco.cc/trials/nct06047379/>, <https://onco.cc/trials/nct06246643/>, <https://onco.cc/trials/correct/>, <https://onco.cc/trials/concur/>, <https://onco.cc/trials/imblaze370/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-grid-regorafenib-gist-lancet-2013/> .